JO3026B1 - مستضادات ببتيد شبيه الجلوكاجون - 2 - Google Patents

مستضادات ببتيد شبيه الجلوكاجون - 2

Info

Publication number
JO3026B1
JO3026B1 JOP/2010/0352A JOP20100352A JO3026B1 JO 3026 B1 JO3026 B1 JO 3026B1 JO P20100352 A JOP20100352 A JO P20100352A JO 3026 B1 JO3026 B1 JO 3026B1
Authority
JO
Jordan
Prior art keywords
agonists
glp
peptidic glp
peptidic
analogs
Prior art date
Application number
JOP/2010/0352A
Other languages
English (en)
Inventor
Riviere Pierre
Sueiras-Diaz Javier
Jiang Guangcheng
Alagarsamy Sudarkodi
Wisniewski Kazimierz
Daniel Schteingart Claudio
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JO3026B1 publication Critical patent/JO3026B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)

Abstract

يتعلق الاختراع الحالي بنظائر GLP-2 جديدة ذات خصائص حركة دوائية محسنة فضلا عن استخدامها في علاج الأمراض.
JOP/2010/0352A 2009-10-23 2010-10-14 مستضادات ببتيد شبيه الجلوكاجون - 2 JO3026B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25449009P 2009-10-23 2009-10-23
EP09173900A EP2314616A1 (en) 2009-10-23 2009-10-23 Peptidic GLP-2 agonists

Publications (1)

Publication Number Publication Date
JO3026B1 true JO3026B1 (ar) 2016-09-05

Family

ID=41572524

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0352A JO3026B1 (ar) 2009-10-23 2010-10-14 مستضادات ببتيد شبيه الجلوكاجون - 2

Country Status (19)

Country Link
US (1) US8580918B2 (ar)
EP (2) EP2314616A1 (ar)
JP (1) JP5755653B2 (ar)
KR (1) KR101794781B1 (ar)
CN (1) CN102711802B (ar)
AR (1) AR079877A1 (ar)
AU (1) AU2010310665B2 (ar)
CA (1) CA2777758C (ar)
DK (1) DK2490709T3 (ar)
ES (1) ES2530615T3 (ar)
JO (1) JO3026B1 (ar)
NZ (1) NZ599137A (ar)
PL (1) PL2490709T3 (ar)
PT (1) PT2490709E (ar)
RS (1) RS53882B1 (ar)
RU (1) RU2551977C2 (ar)
SI (1) SI2490709T1 (ar)
TW (1) TWI482627B (ar)
WO (1) WO2011050174A1 (ar)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015160703A1 (en) * 2014-04-14 2015-10-22 Nps Pharmaceuticals, Inc. Treatment methods for gut-mediated hiv immune dysfunction
US20160067311A1 (en) * 2014-09-10 2016-03-10 Helsinn Healthcare Sa Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
US9783766B2 (en) 2015-04-03 2017-10-10 Ecolab Usa Inc. Enhanced peroxygen stability using anionic surfactant in TAED-containing peroxygen solid
CA3030533A1 (en) 2016-07-11 2018-01-18 Oren HERSHKOVITZ Long-acting coagulation factor vii and methods of producing same
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
US20200254065A1 (en) * 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
IL296464A (en) * 2020-03-16 2022-11-01 Heptares Therapeutics Ltd Oral glp receptor agonists
GB202003762D0 (en) * 2020-03-16 2020-04-29 Heptares Therapeutics Ltd GLP receptor agonists
EP4126004A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonist combination
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN111560061A (zh) * 2020-05-26 2020-08-21 成都圣诺生物制药有限公司 一种Gelpaglutide的制备方法
KR20230038187A (ko) * 2020-06-09 2023-03-17 벡티브바이오 에이지 아프라글루타이드의 제조, 제형화 및 투여
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CA3206093A1 (en) * 2021-01-28 2022-08-04 Violetta Dimitriadou Compositions and methods for the treatment of graft versus host disease
CN116751278B (zh) * 2023-06-21 2024-02-13 杭州信海医药科技有限公司 一种Glepaglutide的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
EP2218734B1 (en) * 1996-04-12 2013-06-05 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US5994500A (en) * 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
JP4280070B2 (ja) * 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
RU2005114512A (ru) * 2002-10-14 2006-12-27 Ново Нордиск А/С (DK) Варианты глюкагон-подобного пептида-2
ATE498631T1 (de) 2005-05-04 2011-03-15 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
US8642727B2 (en) * 2006-11-08 2014-02-04 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues

Also Published As

Publication number Publication date
US8580918B2 (en) 2013-11-12
TW201119668A (en) 2011-06-16
AR079877A1 (es) 2012-02-29
KR101794781B1 (ko) 2017-11-09
SI2490709T1 (sl) 2015-04-30
PT2490709E (pt) 2015-03-04
EP2490709B1 (en) 2014-11-26
CN102711802A (zh) 2012-10-03
JP2013508398A (ja) 2013-03-07
TWI482627B (zh) 2015-05-01
KR20120100942A (ko) 2012-09-12
JP5755653B2 (ja) 2015-07-29
NZ599137A (en) 2013-04-26
EP2490709A1 (en) 2012-08-29
AU2010310665A1 (en) 2012-05-03
WO2011050174A1 (en) 2011-04-28
EP2314616A1 (en) 2011-04-27
PL2490709T3 (pl) 2015-04-30
CN102711802B (zh) 2017-03-22
EP2490709A4 (en) 2013-05-15
AU2010310665B2 (en) 2014-10-23
CA2777758C (en) 2018-06-05
RS53882B1 (en) 2015-08-31
RU2551977C2 (ru) 2015-06-10
ES2530615T3 (es) 2015-03-04
CA2777758A1 (en) 2011-04-28
DK2490709T3 (da) 2015-01-05
RU2012116046A (ru) 2013-11-27
US20120231999A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
JO3026B1 (ar) مستضادات ببتيد شبيه الجلوكاجون - 2
MX2012013375A (es) Peptido c pegilado.
IN2012DN02737A (ar)
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
MX2011007930A (es) Conjugados de insulina cristalina.
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.
MX2012004727A (es) Agonistas peptidicos del glp-2.
IN2012DN03074A (ar)
MX2012012509A (es) Tapentadol para usarse en el tratamiento del sindrome del intestino irritable.
PA8849101A1 (es) Procedimiento de preparación del hemifumarato de eplivanserina
CY1116095T1 (el) Πεπτιδικοι αγωνιστες gla-2
UA41660U (en) Use of jacton and mexidol as actoprotector
UA92646C2 (ru) применение производных 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с актопротекторным действием
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
TH114350B (th) เก้าอี้
UA52376U (ru) Применение КОРВИТИНА в качестве средства фригопротекторного действия
UA52378U (ru) Применение ЛИПОФЛАВОНА в качестве средства фригопротекторного действия
UA52379U (ru) Применение ЛИПИНА в качестве средства фригопротекторного действия
TR200900104U (tr) Çocuk muayene masası.
TH108693B (th) เตียง